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Abstract
Background: Previous studies showed that heparin’s anti-allergic activity is molecular weight dependent and
resides in oligosaccharide fractions of <2500 daltons.
Objective: To investigate the structural sequence of heparin’s anti-allergic domain, we used nitrous acid
depolymerization of porcine heparin to prepare an oligosaccharide, and then fractionated it into disaccharide,
tetrasaccharide, hexasaccharide, and octasaccharide fractions. The anti-allergic activity of each oligosaccharide
fraction was tested in allergic sheep.
Methods: Allergic sheep without (acute responder) and with late airway responses (LAR; dual responder) were
challenged with Ascaris suum antigen with and without inhaled oligosaccharide pretreatment and the effects on
specific lung resistance and airway hyperresponsiveness (AHR) to carbachol determined. Additional inflammatory
cell recruitment studies were performed in immunized ovalbumin-challenged BALB/C mice with and without
treatment.
Results: The inhaled tetrasaccharide fraction was the minimal effective chain length to show anti-allergic activity.
This fraction showed activity in both groups of sheep; it was also effective in inhibiting LAR and AHR, when
administered after the antigen challenge. Tetrasaccharide failed to modify the bronchoconstrictor responses to
airway smooth muscle agonists (histamine, carbachol and LTD4), and had no effect on antigen-induced histamine
release in bronchoalveolar lavage fluid in sheep. In mice, inhaled tetrasaccharide also attenuated the ovalbumin-
induced peribronchial inflammatory response and eosinophil influx in the bronchoalveolar lavage fluid. Chemical
analysis identified the active structure to be a pentasulfated tetrasaccharide ([IdoU2S (1®4)GlcNS6S (1®4) IdoU2S
(1®4) AMan-6S]) which lacked anti-coagulant activity.
Conclusions: These results demonstrate that heparin tetrasaccharide possesses potent anti-allergic and anti-
inflammatory properties, and that the domains responsible for anti-allergic and anti-coagulant activity are distinctly
different.
Introduction
Heparin is a highly sulfated, linear polysaccharide that
has multiple biological activities [1-3]. Heparin inhibits
blood coagulation [1], but also has numerous “non-antic-
oagulant” functions, including interaction with various
growth factors [4,5], modulation of cellular proliferation
[6,7] and regulation of angiogenesis [8]. Heparin also
modulates various proteases and enzymes [9-11] and
possesses anti-inflammatory and immunoregulatory
activities [12-14]. Thus, inhaled heparin has been shown
to inhibit allergic airway responses in sheep [15], as well
as to prevent the bronchoconstrictor responses to exer-
cise and antigen in asthmatic subjects [16-19]. Many bio-
logical actions of heparin, including the anticoagulant
and the anti-allergic activity are molecular weight depen-
dent [20-22]. In allergic sheep, an inverse relationship
between molecular weight and the anti-allergic activity of
fractionated heparin was observed, with ultralow
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fraction [21-23].
The basic polymeric structure of glycosaminoglycan
heparin is an alternating sequence of disaccharide units
comprising of repeating 1®4 linked L-iduronic acid and
D-glucosamine residues [2,3]. The sugar sequence,
degree of sulfation and its high charge density are the
basis of heterogenous molecular organization of heparin
and its ability to interact with various proteins causing
their activation, deactivation, or stabilization [2,3,24].
Heparin’s structural heterogeneity is linked to its multi-
plicity of actions. For example, the binding domain to
antithrombin III [25], and basic fibroblast growth factor
[4] demonstrate the relationship between the fine struc-
ture of heparin derived oligosaccharides and biological
functions. The antithrombin III binding site requires a
minimal pentasaccharide sequence [25], while the bind-
ing domain to basic fibroblast growth factor requires a
hexasaccharide sequence [4].
Consistent with these observations, our previous stu-
dies have demonstrated that the anti-allergic activity of
heparin is independent of its anti-coagulant properties
and resides in oligosaccharide fractions (<2500 daltons)
[23]. However, the exact structural sequence is not
known. Therefore, the purpose of this study was to
identify the minimal chain length and structural
sequence of the anti-allergic domain of heparin. To do
t h i s ,w ep r e p a r e da no l i g o s a c c h a r i d em i x t u r e ,u s e ds i z e -
exclusion chromatography to obtain disaccharide, tetra-
saccharide, hexasaccharide and octasaccharide fractions,
and then determined their anti-allergic activity.
Methods
Ovine Studies
Animal Preparation
All procedures used in this study were approved by the
Mount Sinai Animal Research Committee, which is
r e s p o n s i b l ef o re n s u r i n gt h eh u m a n ec a r ea n du s eo f
experimental animals. Twenty unsedated adult female
sheep, with an average weight of 31 kg (27-36 kg), were
suspended in an upright position in a specialized body
harness in a modified shopping cart, with their heads
secured as published previously [26,15]. All sheep were
allergic to Ascaris suum antigen and had previously been
shown to develop bronchoconstriction following inhala-
tion challenge with the antigen, either without (acute
responders) or with late airway responses (dual respon-
ders) [27].
Airway Mechanics
Measurements of mean pulmonary airflow resistance, in
units of cmH2O/L/s, and thoracic gas volume, in liters,
were made by the esophageal balloon technique and
body plethysmography, respectively, as previously
described [27,15]. Data were expressed as specific lung
resistance (SRL = mean pulmonary airflow resistance ×
thoracic gas volume) in cmH2O/sec.
Aerosol Delivery System
All aerosols were generated using a disposable medical
nebulizer (Raindrop, Puritan Bennett, Lenexa, KS). The
nebulizer was connected to a dosimeter system consist-
ing of a solenoid valve and a source of compressed air.
The output of the nebulizer was directed into a plastic
t-piece, which was interconnected between the inspira-
tory port of the Harvard animal respirator and the
endotracheal tube. The solenoid valve was activated for
1 sec at the beginning of the inspiratory cycle of the
respirator. Aerosols were delivered at a tidal volume of
500 ml and a rate of 20 breaths/minute. Various heparin
oligosaccharide fractions were dissolved in 3 ml of bac-
teriostatic injection water and administered as an aero-
sol over 15-20 minutes. Aerosols of Ascaris suum
extract (diluted 20:1 with phosphate buffered saline;
82000 protein nitrogen units/ml) and carbachol were
also generated with this nebulizer system.
Bronchial Reactivity to Carbachol
To assess baseline airway responsiveness, cumulative
dose-response curves to inhaled carbachol were per-
formed on experiment day 1 by measuring SRL,b e f o r e
and immediately after inhalation of buffered saline and
after each administration of 10 breaths of increasing
concentrations of carbachol (0.25%, 0.5%, 2.0%, 3.0%
and 4.0% wt/vol solution). The bronchoprovocation was
discontinued when SRL increased to 400% above the
baseline. The cumulative provocating dose of carbachol
(in breath units) that increased SRL to 400% above the
baseline was calculated (PD400). One breath unit was
defined as one breath of 1% carbachol solution. Baseline
dose-response curves to carbachol were performed in all
sheep at least 2 weeks after the last exposure to antigen
[27,15,28].
Bronchoalveolar Lavage (BAL)
The distal tip of a specifically designed 80 cm fiberoptic
bronchoscope was wedged into a randomly selected sub-
segmental bronchus. BAL was performed by an infusion
and gentle aspiration of 30 ml aliquots of phosphate buf-
fered saline (pH 7.4) at 39°C, using 30 ml syringes
attached to the working channel of the bronchoscope.
The effluent was filtered through a single layer of gauze
and placed immediately on ice. The volume of the efflu-
ent collected from the BAL fluid was measured and cen-
trifuged at 420 g, at 4°C for 15 minutes. The supernatant
was decanted and centrifuged again at 1000 g, at 4°C for
15 minutes. The supernatant was frozen at -80°C for sub-
sequent histamine analysis.
Histamine Radioimmunoassay
Duplicate aliquots from each BAL sample were used for
histamine radioimmunoassay using a commercial kit from
Immunotech International (AMAC Inc; Westerbrook,
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ficient of variation is <10%. There is less than 0.1% cross-
reactivity with histidine, serotonin or t-methyl histamine.
Murine Studies
These studies were also approved by the Mount Sinai Ani-
mal Research Committee. Female BALB/c mice, 4-6 weeks
old were immunized by injecting intra-peritoneally with
0.2 ml of 0.05% solution of ovalbumin adsorbed to alum
on day 1 and again on day 14. On days 25, 26, & 27, the
animals were placed in an exposure chamber for ovalbu-
min aerosol challenge (3% ovalbumin for 30 minutes).
Aerosols were generated using a PARi IS-2 nebulizer at a
flow rate of 6 l/min. 24 hours later, on day 28, the mice
were sacrificed, the trachea was carefully dissected and a
blunt needle was inserted. Bronchoalveolar lavage (BAL)
was performed with freshly prepared phosphate buffered
saline (PBS, 0.8 ml) at 4°C. The BAL fluid was centrifuged
at 1500 RPM for 10 minutes. The supernatant was sepa-
rated and the pellet was resuspended in PBS to a volume
of 0.3 ml, and centrifuged again at 650 RPM for 10 min-
utes. The slides were prepared and stained with a Giemsa-
Wright stain. In some mice, after the BAL was completed,
the lungs were dissected, fixed in formalin and embedded
in paraffin for histology. The tissues were cut into 3 um
sections and stained with hematoxylin and eosin stain.
Preparation of Heparin Oligosaccharides
An aqueous solution of porcine intestinal heparin (USP)
was depolymerized at room temperature with HNO2,
generated in situ from HCl and NaNO2 (pH: 1.5). After
one hour, the reaction pH was raised to 10 by addition
of aqueous NaOH. The solution was then reacted with
NaBH4 for 18 hours to reduce the aldehyde group in
the terminal 2,5-anhydro-D-mannose, obtained in the
initial depolymerization step [29]. Reaction mixture was
then neutralized and subjected to freeze-drying, which
yielded the sodium salt of oligosaccharide mixture. Size
exclusion gel chromatography of the oligosaccharide
mixture was performed on 1.5 M × 80 cm column, con-
taining BioRad P4 Biogel (10 L) and eluting with 0.2 M
NH4HCO3. After lyophilization, an ammonium salt of
the appropriate fractions was obtained. The salt form
was exchanged to sodium by passing the aqueous solu-
tion of the ammonium salt of each fraction through a
column containing Amberlite 1R 120 PLUS cation-
exchange Resin (Sigma Aldrich Chemical Co.). Finally,
after freeze-drying the sodium salt of each oligosacchar-
ide fraction (i.e. disaccharide, tetrasaccharide, hexasac-
charide and octasaccharide) was collected.
Characterization of Heparin Oligosaccharides
The size of the sodium salt of each heparin-derived oligo-
saccharide fraction, including disaccharide, tetrasaccharide,
hexasaccharide and octasaccharide was determined by size
exclusion HPLC [30]. Further structural confirmation of
the disaccharide, tetrasaccharide, hexasaccharide fractions
was obtained by
1H-NMR,
13C-NMR, and Mass Spectro-
metry [30-32].
Experimental Protocol
Ovine Studies:
A. Effect of Heparin Oligosaccharides in Acute Responders
For the control experiment, after the baseline measure-
ments of SRL, the sheep (n = 6) were challenged with aero-
solized antigen and measurements of SRL were repeated
within five minutes post-challenge. To evaluate the effect
of heparin oligosaccharides on this antigen-induced
response, dose-response studies were performed. The
inhaled doses of various oligosaccharides used were: (a)
oligosaccharide mixture (n = 6) 0.25 mg/kg, 0.5 mg/kg
and 1 mg/kg; (b) octasaccharide (n = 5), 0.125 mg/kg,
0.25 mg/kg, and 0.5 mg/kg; (c) hexasaccharide (n = 5),
0.03 mg/kg, 0.06 mg/kg and 0.125 mg/kg; (d) tetrasacchar-
ide (n = 5), 0.03 mg/kg, 0.06 mg/kg and 0.125 mg/kg;
(e) disaccharide (n = 3) was evaluated only at a dose of
4 mg/kg. The sheep were pretreated with different doses
of oligosaccharides, 30 minutes before the antigen chal-
lenge and measurements of SRL were repeated within five
minutes post antigen challenge. The interval between tests
with each dose of the different oligosaccharide fractions
was at least two weeks.
B. Effect of Heparin Oligosaccharides in Dual Responders
(n = 6)
For every oligosaccharide tested, each sheep was studied
on three different experiment days. For the control
experiments, baseline bronchial reactivity to carbachol
(PD400) was determined on experiment day 1. On
experiment day 2, after the baseline measurements of
SRL, each animal was challenged with aerosolized
Ascaris suum antigen. Repeat measurements of SRL
were obtained within five minutes after the antigen chal-
lenge, and serially for up to eight hours for demonstra-
tion of early airway response (EAR) and late airway
response (LAR). Twenty-four hours after the antigen
challenge, bronchial reactivity to carbachol was re-deter-
mined (experiment day 3) as an index of antigen-
induced airway hyperresponsiveness (AHR).
The above-mentioned 3-day protocol was repeated, at
least two weeks apart for each dose of the oligosacchar-
ide tested. In each sheep, the baseline PD400 of carba-
chol was determined on experiment day 1, followed by
experiment day 2, when the sheep were pretreated with
the different doses of the inhaled oligosaccharides, 30
minutes before the antigen challenge and then on
experiment day 3, the PD400 was re-determined. The
doses of oligosaccharides used were: (a) oligosaccharide
mixture 0.5 mg/kg; (b) octasaccharide, 0.5 mg/kg;
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0.03 mg/kg, 0.06 mg/kg and 0.125 mg/kg.
Post-Antigen Administration of Tetrasaccharide (n = 5)
To evaluate the effect of “post-antigen” administration of
tetrasaccharide on LAR and AHR, the 3-day protocol
described above was repeated, except that instead of pre-
treating the animals, the doses of tetrasaccharide (0.03
mg/kg; 0.06 mg/kg; 0.125 mg/kg) were administered
immediately after the post-antigen measurements of SRL.
C. Agonist-Induced Bronchoconstriction (n = 3)
After obtaining the baseline measurements of SRL,t h e
sheep were challenged with aerosolized carbachol (10
breaths of 2% solution; n = 3) histamine (50 breaths of 5%
solution; n = 3) or leukotriene (LT)D4 (20 breaths of
0.01% solution; n = 3) and measurements of SRL were
repeated immediately after. On separate days, the sheep
were pretreated with inhaled tetrasaccharide (0.125 mg/
kg) 30 minutes before agonist challenge and then the
above protocols were repeated.
D. Histamine Release in BAL (n = 6)
In each animal BAL was performed on two different
experiment days, at least two weeks apart, before and after
a segmental antigen-challenge, without and after pretreat-
ment with inhaled tetrasaccharide (0.125 mg/kg). Tetra-
saccharide was nebulized 30 minutes before the segmental
antigen challenge. Ascaris suum antigen (2.5 ml Ascaris
suum and 2.5 ml buffer) was infused via a wedged
bronchoscope and BAL was performed 20 minutes later.
The BAL effluent was centrifuged and the supernatant
saved and frozen at -80°C for subsequent RIA.
Murine Studies
The mice were immunized with intraperitoneal injection
of ovalbumin (0.2 ml of 0.05% solution) on day 1 and
again on day 14. On days 25, 26 and 27, the negative con-
trol group (n = 4) received an aerosol of normal saline,
while the positive control group (n = 5) was challenged
with an aerosol of 3% ovalbumin for 30 minutes. On day
28, the mice were sacrificed and BAL and lung tissue were
prepared for estimation of eosinophil influx and airway
inflammation. For the treatment group (n = 4), the mice
were pretreated with aerosolized tetrasaccharide (0.3%
solution) on days 25, 26, and 27, one hour before ovalbu-
min challenge, and the above mentioned day 28 protocol
was repeated. Histological specimens were obtained from
one mouse in each group for representative purposes only.
Statistical Analysis
T h ed a t aw e r ee x p r e s s e da sm e a n±S E .T h eS R L data
were analyzed by a two-way analysis of variance with
repeated measures, followed by Newman-Keuls pairwise
comparison. Area Under the Curve for EAR AUC 0-4h
and LAR AUC 4-8h were calculated using the trapezoid
rule for the treatment and control arms in the same
animals and compared using a paired t-test. The base-
line values of PD400 were compared to post-antigen
PD400 (without and with oligosaccharide) by Friedman’s
t w o - w a yA n a l y s i so fV a r i a n c ef o l l o w e db yn o n - p a r a -
metric multiple comparison. Histamine concentration in
the sheep BAL was analyzed by a paired t-test. Mouse
BAL celluar analysis was first analyzed with a one way
analysis of variance followed by Student-Newman-Keuls
method to detect pairwise differences. Significance was
accepted at P < 0.05.
Results
Effect of Heparin Oligosaccharides in Acute Responders
In acute responders (n = 6), mean ± SE peak SRL
increased by 263 ± 45% with antigen alone. We first
tested the oligosaccharide mixture to insure that it had
anti-allergic activity similar to what we had seen pre-
viously with ultra low molecular weight heparins
[21,22]. The inhaled oligosaccharide mixture (MW:1930
daltons) significantly attenuated the peak antigen-
induced bronchoconstrictor response (ABR) by 51 ±
10%, 49 ± 9% and 67 ± 7% at doses of 0.25 mg/kg,
0.5 mg/kg and 1 mg/kg, respectively (Figure 1).
Dose response studies with various fractions, isolated
from the heparin-oligosaccharide mixture, showed that
octasaccharide was the least potent compared to hexa-
saccharide and tetrasaccharide which were equipotent at
the doses tested (Figure 1). The octasaccharide fraction
(n = 5, MW:2480 daltons) attenuated the ABR by 32 ±
8% (P = NS), 61 ± 11% (P < .05), and 65 ± 9% (P < .05),
at doses of 0.125 mg, 0.25 mg/kg and 0.5 mg/kg, respec-
tively. The hexasaccharide fraction (n = 5, MW: 1890
daltons) attenuated the ABR by 3 ± 6% (P = NS), 69 ±
10% (P < .05), and 83 ± 7% (P < .05) at doses of 0.03
mg/kg, 0.06 mg/kg and 0.125 mg/kg, respectively. Simi-
larly, the tetrasaccharide fraction (n = 5, MW: 1231 dal-
tons) attenuated the ABR by 26 ± 8% (P = NS), 67 ± 7%
(P < .05) and 71 ± 7% (P < .05) at doses of 0.03 mg/kg,
0.06 mg/kg and 0.125 mg/kg, respectively. Based on
these findings, we considered the 0.5 mg/kg, 0.125 mg/
kg and 0.125 mg/kg doses of octasaccharide, hexasac-
charide and tetrasaccharide fractions, respectively to be
most effective against ABR., At these doses, the octasac-
charide fraction was two-fold more potent, and the
tetrasaccharide and hexasaccharide fractions were eight-
fold more potent than the oligosaccharide mixture.
Effect of Heparin Oligosaccharides in Dual Responders
Having achieved significant inhibition of the ABR in
acute responders, we next tested the activity of the oli-
gosaccharides doses identified above in “Dual Respon-
ders’’. In this group (n = 6), antigen-induced changes in
SRL without and after pretreatment with the inhaled
heparin oligosaccharides are shown in figure 2. With
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353 ± 74% and 190 ± 30%, respectively. The corre-
sponding early response area under the curve (EAR
AUC0-4h) and late response area under the curve (LAR
AUC4-8h) were 577 ± 132% and 353 ± 73%, respectively.
Pretreatment with the inhaled oligosaccharide mixture
(0.5 mg/kg) inhibited the antigen-induced increases in
SRL. Peak early and peak late increases in SRL with pre-
treatment were 140 ± 21% and 77 ± 19%, respectively
(P < .05). This translated to an inhibition of EAR AUC0-
4h and LAR AUC4-8h by 60 ± 15%and 52 ± 8%, respec-
tively (P < .05, Figure 2). Heparin-derived oligosacchar-
ide mixture also inhibited the antigen-induced AHR. In
the control trial, the 24 hours post-antigen, mean ± SE
PD400 decreased from 19 ± 1 breath units to 10 ± 2
breath units; this was prevented by the heparin oligosac-
charide mixture (PD400 = 20 ± 4 breath units). (P < .05,
Figure 3).
The octasaccharide fraction of heparin (n = 3; 0.5 mg/
kg) inhibited the EAR AUC0-4h by 74 ± 10% and LAR
AUC4-8h by 75 ± 2% (P < .05); while the antigen-
induced AHR was inhibited by 100 ± 7%, (P < .05). The
hexasaccharide fraction (n = 5; 0.125 mg/kg) inhibited
the EAR AUC0-4h by 61 ± 8% and LAR AUC4-8h by 81
± 6% (P < .05); while antigen-induced AHR was inhib-
ited by 80 ± 13% (P < .05); respectively. The anti-allergic
activity of the tetrasaccharide fraction (n = 5; 0.125 mg/
kg) was comparable to the hexasaccharide fraction
(Figure 2, 3). Figure 4 shows that the anti-allergic activ-
ity of the tetrasaccharide fraction was dose-dependent.
While 0.03 mg/kg (n = 5) dose was ineffective, the 0.06
mg/kg (n = 6) and 0.125 mg/kg (n = 5) doses inhibited
the EAR AUC0-4h by 47 ± 13% and 63 ± 11% (P < .05);
LAR AUC4-8h by 63 ± 7% and 81 ± 9% (P < .05). Anti-
gen-induced AHR at these doses was inhibited by 95 ±
9% and 100 ± 10% (P < .05); respectively.
Post-antigen administration of Tetrasaccharides
Inhaled tetrasaccharide (n = 5) caused a dose-dependent
inhibition of LAR AUC4-8h and AHR when administered
“after” the antigen challenge (Figure 5). While 0.03 mg/kg
dose was ineffective, post-antigen administration of
0.06 mg/kg tetrasaccharide inhibited the LAR AUC4-8h
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Figure 1 Effect of inhaled heparin-oligosaccharides on antigen-induced bronchoconstrictor response in “Acute Responder” sheep. Data
are shown as % change in specific lung resistance (SRL) ± SE without and after pretreatment with different dose of oligosaccharide mixture (n =
6) and various fractions including octasaccharide (n = 5), hexasaccharide (n = 5) and tetrasaccharide(n = 5). *Significantly different from antigen
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tively. The effects of 0.06 mg/kg and 0.125 mg/kg doses of
tetrasaccharide were comparable.
Minimal effective chain length
Heparin derived tetrasaccharide was the minimum effec-
tive chain length possessing the anti-allergic activity.
The disaccharide fraction was ineffective in both “acute”
and “dual” responder sheep. Inhaled disaccharide at a
32-fold higher dosage than tetrasaccharide had no effect
on antigen-induced ABR in “acute responders” (Figure
6, Top). Similarly an 8-fold excess of disaccharide had
no effect in dual responders (Figure 6, Bottom).
Agonist-induced bronchoconstriction
The inhaled tetrasaccharide fraction (0.125 mg/kg) failed
to modify the bronchoconstrictor responses to histamine
(n = 3), carbachol (n = 3) and LTD4 (n = 3). The mean ±
SE SRL values without and after pretreatment with
inhaled tetrasaccharide were 509 ± 6% vs. 515 ± 5% (P =
NS); 333 ± 21% vs. 368 ± 23% (P = NS); and 210 ± 35%
vs. 222 ± 19% (P = NS) for histamine, carbachol and
LTD4, respectively.
Histamine Release in BAL
Baseline concentration of histamine in BAL (n = 6) was
0.4 ± 0.2 nM and 0.5 ± 0.2 nM. Segmental antigen chal-
lenge caused a marked increase in BAL histamine concen-
tration (8.5 ± 7.1 nM), which was not inhibited by
pretreatment with inhaled tetrasaccharide (9.8 ± 8.1 nM).
Antifactor Xa-activity
In vitro the tetrasaccharide fraction had no anti-coagulant
activity; the antifactor-Xa activity of tetrasaccharide frac-
tion was 0.8 I.U.; while hexasaccharide and octasaccharide
fractions had antifactor-Xa activity of 1.8 I.U. and 27 I.U.,
respectively.
Murine Studies
In ovalbumin immunized mice, aerosolized ovalbumin
(+controls) produced a marked perivascular and peri-
bronchial inflammatory response and caused a
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Page 7 of 13significant increase in total cells and eosinophils in the
BAL compared to immunized but saline challenged ani-
mals (-controls, Table 1). Pretreatment with aerosolized
heparin-tetrasaccharide in immunized and ovalbumin
challenged mice inhibited the inflammatory response in
the peribronchial and perivascular regions (Figure 7).
This histological finding was supported by the data in
Table 1, which shows that heparin tetrasaccharide pre-
treatment reduced the total number of cells by 41%, the
total number of eosinophils by 62% and the % eosino-
phils by 37% (all P < 0.05) when compared to the + con-
trols. Table 1 also shows that there was a significant
increase in the % macrophages and % neutrophils in the
tetrasaccharide pretreated animals when compared to the +
controls. However, calculation of the total neutrophil num-
ber shows the tetrasaccharide treated group (0.06 × 10
6 ±
0.01) and the + control group (0.06 × 10
6 ± 0.02) not to be
different.
Chemical Structure Analysis
Chemical structure analysis showed that the size-defined
heparin-tetrasaccharide fraction is a mixture of tetrasac-
charides. It predominantly consists of a pentasulfated tet-
rasaccharide (approximately 80%), along with other
tetrasaccharides that have fewer sulfate moieties. The pen-
tasulfated tetrasaccharide has a molecular weight of 1231
daltons. Its chemical structure consists of 2-O-sulfo- L-
iduronic acid (1 ® 4) 6-O, N-disulfo-D-glucosamine (1 ®
4) 2-O-sulfo- L-iduronic acid (1 ® 4) 6-O-sulfo-2,5-Anhy-
dro-D-Mannitol [IdoU2S (1 ® 4)GlcNS6S (1 ® 4)
IdoU2S (1 ® 4) AMan-6S] (Figure 8).
Discussion
Many biological actions of heparin, including the anti-
allergic activity are molecular weight dependent [20-22].
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Figure 6 Failure of inhaled heparin disaccharide to inhibit
allergic bronchoconstrictor responses in sheep. Top: Antigen-
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Responders” with (4 mg/kg; n = 3) and without pretreatment
(control). Bottom: “Dual Responders” (1 mg/kg, n = 3,) without
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Table 1 Effect of heparin tetrasaccharide on ovalbumin (OVA) induced changes in inflammatory cell influx in BAL of
mice
Total Total % % % % % %
Cells Eosinophils Eosinophils Epithelial Macrophages Lymphocytes Neutrophils Monocytes
(-) Control
(n = 4)
0.46 × 10
6 0.8 × 10
3 0.2% 1.1% 94.2% 3.1% 0.2% 1.2%
(0.04) (0.3) (0.1) (0.6) (2.6) (2.0) (0.1) (0.4)
(+) Control
(n = 5)
*1.02 × 10
6 *0.45 × 10
6 *44.3% 2.3% *30.1% *16.9% *5.6% 0.8%
(0.15) (0.08) (6.0) (1.1) (5.4) (2.1) (1.2) (0.5)
Tetrasaccharide
(n = 4)
†0.60 × 10
6 †*0.17 × 10
6 †*27.7% 3.7% †* 42.8% *12.4% †*9.5% 1.1%
(0.01) (0.01) (0.9) (1.3) (3.5) (1.6) (1.7) (0.2)
Data are shown as mean (SE).
(-) Control (OVA sensitized/saline challenge)
(+) Control (OVA sensitized/OVA challenge)
Tetrasaccharide (Treatment group/OVA challenge)
* p < .05 from (-) control
† p < .05 from (+) control
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Page 8 of 13Figure 7 Lung histology samples in ovalbumin immunized mice. Top Panel: Control mice challenged with aerosolized saline; there is no
evidence of peribronchial and perivascular inflammation. Middle Panel: Mice challenged with aerosolized ovalbumin; marked peribronchial and
perivascular inflammation is seen with eosinophil infilteration. Bottom Panel: Ovalbumin challenged mice after pretreatment with nebulized
heparin tetrasaccharide; reduced peribronchial and perivascular inflammation. Hematoxylin and eosin stain ( × 64 magnification).
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Page 9 of 13Previous studies in sheep have demonstrated that
unfractionated heparin inhibited the allergic airway
responses only in “acute responders”, while it was inef-
fective in “dual responders” [33]. In the “acute respon-
der” sheep, the anti-allergic activity of fractionated
heparin was molecular-weight dependent; and ultra low
molecular weight heparin was found to be the most
potent fraction [21,22]. We have also observed that the
anti-allergic activity of fractionated heparin in the “dual
responder” sheep is critically dependent on molecular
weight. Only the ultra-low molecular weight heparin
attenuated the antigen-induced EAR, LAR and AHR,
while unfractionated heparin, medium molecular weight
heparin and low molecular weight heparin were ineffec-
tive [23]. Thus, the ultra low molecular weight heparins
(<2500 dalton) are qualitatively unique and inhibit aller-
gic airway responses in both the acute and the dual
responder sheep [21-23]. Although the anti-allergic
activity of heparin is independent of its anticoagulant
properties, the exact structural sequence and the chain-
length possessing the anti-allergic activity is not known.
The results of present study further extend our previous
observations and demonstrate that: (a) the anti-allergic
activity of heparin resides in a tetrasaccharide sequence,
(b) the domains responsible for anticoagulant and anti-
allergic activity of heparin are distinctly different, and
(c) heparin tetrasaccharide possesses anti-inflammatory
properties.
The heparin-derived oligosaccharide mixture used in
the present study attenuated the allergic airway
responses in both “acute” and “dual” responder sheep
(figure 1 and 2). Its average molecular weight is 1930
daltons, and its anti-allergic activity is comparable to
other oligosaccharides (mol wt 2200-2400 daltons) stu-
died previously [21-23]. The size exclusion chromato-
graphic analysis of heparin-derived oligosaccharide
mixture showed that it is a heterogenous mixture, con-
sisting of disaccharide, tetrasaccharide, hexasaccharide,
octasaccharide and some decasaccharide fractions. Our
data with different fractions revealed that the minimal
oligosaccharide chain length possessing anti-allergic
activity was a tetrasaccharide as disaccharide was inef-
fective. The tetrasaccharide, hexasaccharide and octasac-
charide fractions inhibited the allergic airway responses
in both “acute” and “dual” responders in a dose-depen-
dent manner; however, the relative potency of each oli-
gosaccharide increased with the smaller fractions. In the
“acute responders”, the octasaccharide fraction was two-
fold more potent than the oligosaccharide mixture,
while tetrasaccharide and hexasaccharide fractions were
approximately eight-fold more potent. In the “dual
responders”, the anti-allergic activity of the octasacchar-
ide fraction was comparable to the oligosaccharide mix-
ture, while the hexasaccharide and the tetrasaccharide
fractions were four-fold more potent. The results of this
study also demonstrate that the tetrasaccharide fraction
was also effective in inhibiting LAR and AHR, when
administered after the antigen challenge. This action
suggests possible anti-inflammatory activity as the LAR
and AHR are pathophysiological indices of airway
inflammation [27,28]. This conclusion is also supported
by the mouse data (see below).
The heterogenous structure of glycosaminoglycan
heparin is linked to its functional polydispersity. The
biological activities of heparin are primarily mediated
through its binding of various proteins and enzymes,
PENTASULFATED TETRASACCHARIDE
Figure 8 Chemical structure of heparin-derived pentasulfated tetrasaccharide.
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Page 10 of 13but only the anti-thrombin III binding site involved in
the anticoagulant action has been clearly elucidated as a
distinct pentasaccharide sequence [25]. A hexasacchar-
ide fraction has been suggested as the minimal chain
length required to bind to fibroblast growth factor and
transforming growth factor-b, as well as possessing anti-
proliferative activity on vascular smooth muscle cells
[4,5,7,6]. The results of our studies demonstrate that
heparin tetrasaccharide was the minimal chain length
possessing the anti-allergic activity. Furthermore, the
results of our studies are novel in that they demonstrate
the unmasking of a biological action of heparin derived
oligosaccharide (e.g. inhibition of LAR and AHR), which
was not observed in unfractionated heparin or heparin
fractions with molecular weight of >2500 daltons.
The basic structure of heparin consists of an alternat-
ing sequence of disaccharide units comprising of repeat-
ing 1®4 linked L-iduronic acid and D-glucosamine
residues, which are variably sulfated [3,2]. However, the
fine structure of heparin disaccharide units and its sulfa-
tion pattern varies with the method of depolymerization.
The heparin oligosaccharides used in this study were pro-
duced by controlled nitrous acid depolymerization of
porcine heparin, resulting in terminal glucosamine ring
contraction to 2,5-anhydro-mannose and followed by its
reduction to 2,5-anhydro-mannitol moiety. The tetrasac-
charide fraction predominantly consists of a pentasul-
fated tetrasaccharide with a molecular weight of 1231
daltons. Its chemical structure consists of IdoU2S (1 ®
4) GlcNS6S (1 ® 4) IdoU2S (1 ® 4) AMan-6S. Besides
2-0 and 6-0 sulfation, it has N-sulfation of the inner glu-
cosamine ring, while the terminal glucosamine has ring
contraction to 2,5-Anhydro-D-Mannitol-6S.
The anticoagulant action of heparin is predominantly
mediated by binding of antithrombin III, which requires
a pentasaccharide sequence with 3-0 sulfation of the
inner glucosamine ring [25]. Previous studies in human
subjects and sheep have suggested that the anti-allergic
activity of inhaled heparin is independent of its anticoa-
gulant properties, as APTT and antifactor-Xa activity
were not prolonged [15,17,18,16]. This was also sup-
ported by the observations that non-anticoagulant frac-
tions of heparin had potent anti-allergic activity
[22,23,34]. The results of present study confirm this
hypothesis. The heparin derived tetrasaccharide has an
antifactor Xa activity of 0.8 IU; it also lacks critical 3-0
sulfation of the inner glucosamine ring, and its chain
length is below the pentasaccharide sequence needed for
anticoagulant activity. Collectively, these facts support
the concept that the domains responsible for anti-coagu-
lant and anti-allergic activity of heparin are distinctly
different.
The mechanism of the anti-allergic activity of heparin
derived oligosaccharides including the tetrasaccharide
fraction is not known at present. Heparin derived tetra-
saccharide failed to modify the bronchoconstrictor
responses induced by the smooth muscle agonists,
including histamine, carbachol or LTD4; thus excluding
a direct effect on airway smooth muscle. The tetrasac-
charide fraction had no effect on antigen-induced hista-
mine release in BAL. It has been proposed that the anti-
allergic activity of unfractionated heparin in acute
r e s p o n d e r sm a yb em e d i a t e db yi n h i b i t i o no fI P 3 -
dependent mast cell mediator release [35]. The inhibi-
tion of IP3 binding to its receptors by heparin is mole-
cular weight dependent and the inhibitory activity
decreases as the size of the heparin chain is reduced
below 18 monosccharide units [36]. While fractions,
containing 10-14 monosaccharide units, had substan-
tially lower activity, the 8 monosaccharide fractions had
none [36]. Thus, it is unlikely that the anti-allergic activ-
ity of heparin derived tetrasaccharide is related to inhi-
bition of IP3-dependent mast cell mediator release. This
is supported by our observation that the heparin derived
tetrasaccharide failed to modulate antigen-induced hista-
mine release in BAL fluid. The failure to modulate BAL
histamine release but still have anti-allergic activity
(blocking of EAR, LAR and AHR) is also consistent with
our previous work which showed that structural domain
of the heparin molecule responsible for this anti-allergic
activity resides in the glycosaminoglycan chain length of
<2500 daltons, whereas, the histamine-release inhibitory
activity domain is located in the chain length of >2500
daltons [22,23]. As indicated above, all the fractions stu-
died here were less < 2500 daltons.
The unfractionated heparin and low molecular weight
heparins have been suggested to possess anti-inflamma-
tory properties [37-40]. The attenuation of allergic air-
way responses without inhibition of histamine released
in the BAL suggests that the in vivo activity of heparin
tetrasaccharide may be mediated by a yet unknown anti-
inflammatory mechanism. The inhibition of LAR and
AHR by heparin tetrasaccharide, when administered
after the antigen challenge supports this concept, as the
immediate response to allergen is unimpaired, yet LAR
and AHR, the primary physiological responses reflecting
antigen-induced inflammation were blocked [41,28].
This concept is also supported by the observation that
aerosolized heparin-tetrasaccharide caused a reduction
in the allergen-induced eosinophil influx in the BAL
fluid of ovalbumin sensitized mice and attenuated the
peribronchial and perivascular inflammatory cell infiltra-
tion. The collective data supporting the anti-inflamma-
tory actions of heparin tetrasaccharide seen here are
consistent with reports that unfractionated heparin and
heparin oligosaccharides, including tetrasaccharides, are
effective inhibitors of L- P- selectins and demonstrate
anti-inflammatory activity in vivo [42-44]. For example,
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reduce neutrophil influx in thioglycollate-induced peri-
toneal inflammation in mice [42], a process which has
been shown to involve stimulation of both L- and
P-selectin. Finally, the potential role of anti-selectin
action of heparin tetrasaccharide in inhibiting allergic
airway responses would also be consistent with our pre-
vious observation in sheep, showing attenuation of LAR
and AHR by selectin inhibitors [45].
Although this study provides unique and novel data
with regards to the anti-allergic and anti-inflammatory
actions of oligosaccharides there are limitations. One
short coming is that we are unclear as to the exact
mechanism by which these oligosaccharides provide
their protective effects. Having now described that the
tetrasaccharide fraction is the minimal chain length to
demonstrate these properties we can use this molecule
to focus on the actual mechanism(s) involved in pre-
venting these allergic responses. We should also point
out that we did not measure the effects of these oligo-
saccharides on small airway function in this study.
While our previous work has identified small airway
dysfunction (i.e. decreased dynamic compliance) follow-
ing allergen provocation [27], many of the studies
designed to test the effects of agents on allergen-
i n d u c e dE A R ,L A Ra n dA H Rh a v en o ti n v o l v e dt h e s e
measures because SRL is more easily related to measures
of airway function in patients in clinical trials (i.e. speci-
fic airway conductance or FEV1). Thus, while our data
provides evidence that these oligosaccharides can modu-
late large airway effects associated with allergen chal-
lenge, we cannot categorically assume that small airway
function was protected to a similar extent.
In conclusion, we have demonstrated for the first time
that heparin tetrasaccharide is the minimal chain length
that possesses anti-allergic and anti-inflammatory prop-
erties and these actions are distinct from any anti-coa-
gulant properties. Our findings showing that both pre
and post treatment modulate LAR and AHR, support
the possibility that heparin oligosaccharides may inter-
rupt multiple diverse cellular events involved in the
complex cascade of allergic airway inflammation.
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